Introducing drug transport early in the design of hypoxia selective anticancer agents using a mathematical modelling approach

SEMA SIMAI Springer Series

Volumn , Issue 9788847025707, 2012, Pages 337-353

  Hicks, Kevin ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85033480185     PISSN: 21993041     EISSN: 2199305X     Source Type: Book Series    
DOI: 10.1007/978-88-470-2571-4_18     Document Type: Chapter

References (42)

1. Brown, J.M.: Tumor hypoxia in cancer therapy. Methods Enzymol. 435, 297–321 (2007)
2. Brown, J.M.: Henry S. Kaplan Distinguished Scientist Award Lecture 2007. The remarkable yin and yang of tumour hypoxia. Int. J. Radiat. Biol. 86, 907–917 (2010)
3. Brown, J.M., Wilson, W.R.: Exploiting tumor hypoxia in cancer treatment. Nat. Rev. Cancer 4, 437–447 (2004)
4. Cowan, D.S., Hicks, K.O., Wilson, W.R.: Multicellular membranes as an in vitro model for extravascular diffusion in tumours. Br. J. Cancer Suppl. 27, S28–S31 (1996)
5. Dewhirst, M.W.: Concepts of oxygen transport at the microcirculatory level. Semin. Radiat. Oncol. 8, 143–150 (1998)
6. Dewhirst, M.W., Ong, E.T., Klitzman, B., Secomb, T.W., Vinuya, R.Z., Dodge, R., Brizel, D., Gross, J.F.: Perivascular oxygen tensions in a transplantable mammary tumor growing in a dorsal flap window chamber. Radiat. Res. 130, 171–182 (1992)
7. Dewhirst, M.W., Secomb, T.W., Ong, E.T., Hsu, R., Gross, J.F.: Determination of local oxygen consumption rates in tumors. Cancer Res. 54, 3333–3336 (1994)
8. Durand, R.E., Olive, P.L.: Evaluation of bioreductive drugs in multicell spheroids. Int. J. Radiat. Oncol. Biol. Phys. 22, 689–692 (1992)
9. Durand, R.E., Olive, P.L.: Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice. Radiat. Oncol. Investig. 5, 213–219 (1997)
10. Gillies, R.J., Schornack, P.A., Secomb, T.W., Raghunand, N.: Causes and effects of heterogeneous perfusion in tumors. Neoplasia 1, 197–207 (1999)
11. Hay, M.P., Hicks, K.O., Pchalek, K., Lee, H.H., Blaser, A., Pruijn, F.B., Anderson, R.F., Shinde, S.S., Wilson, W.R., Denny, W.A.: Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins. J. Med. Chem. 51, 6853–6865 (2008)
12. Hay, M.P., Hicks, K.O., Pruijn, F.B., Pchalek, K., Siim, B.G., Wilson, W.R., Denny, W.A.: Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport. J. Med. Chem. 50, 6392–6404 (2007)
13. Hay, M.P., Pchalek, K., Pruijn, F.B., Hicks, K.O., Siim, B.G., Anderson, R.F., Shinde, S.S., Phillips, V., Denny, W.A., Wilson, W.R.: Hypoxia-selective 3-alkyl 1,2,4-benzotriazine 1,4-dioxides: the influence of hydrogen bond donors on extravascular transport and antitumor activity. J. Med. Chem. 50, 6654–6664 (2007)
14. Hicks, K.O., Fleming, Y., Siim, B.G., Koch, C.J., Wilson, W.R.: Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model. Int. J. Radiat. Oncol. Biol. Phys. 42, 641–649 (1998)
15. Hicks, K.O., Myint, H., Patterson, A.V., Pruijn, F.B., Siim, B.G., Patel, K., Wilson, W.R.: Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine. Int. J. Radiat. Oncol. Biol. Phys. 69, 560–571 (2007)
16. Hicks, K.O., Ohms, S.J., van Zijl, P.L., Denny, W.A., Hunter, P.J., Wilson, W.R.: An experimental and mathematical model for the extravascular transport of a DNA intercalator in tumours. Br. J. Cancer 76, 894–903 (1997)
17. Hicks, K.O., Pruijn, F.B., Secomb, T.W., Hay, M.P., Hsu, R., Brown, J.M., Denny, W.A., Dewhirst, M.W., Wilson W.R.: Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J. Natl. Cancer Inst. 98, 1118–1128 (2006)
18. Hicks, K.O., Pruijn, F.B., Sturman, J.R., Denny, W.A., Wilson, W.R.: Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures. Cancer Res. 63, 5970– 5977 (2003)
19. Hicks, K.O., Siim, B.G., Jaiswal, J.K., Pruijn, F.B., Fraser, A.M., Patel, R., Hogg, A., Liyan-age, H.D.S., Dorie, M.J., Brown, J.M., Denny, W.A., Hay, M.P., Wilson, W.R.: Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin. Cancer Res. 16, 4946–4957 (2010)
20. Hicks, K.O., Siim, B.G., Pruijn, F.B., Wilson, W.R.: Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors. Radiat. Res. 161, 656–666 (2004)
21. Hsu, R., Secomb, T.W.: A Green’s function method for analysis of oxygen delivery to tissue by microvascular networks. Math. Biosci. 96, 61–78 (1989)
22. Koch, C.J.: Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res. 53, 3992–3997 (1993)
23. Kyle, A.H., Minchinton, A.I.: Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model. Cancer Chemother. Pharmacol. 43, 213–220 (1999)
24. Minchinton, A.I., Tannock, I.F.: Drug penetration in solid tumours. Nat. Rev. Cancer 6, 583– 592 (2006)
25. von Pawel, J., von Roemeling, R., Gatzemeier, U., Boyer, M., Elisson, L.O., Clark, P., Talbot, D., Rey, A., Butler, T.W., Hirsh, V., Olver, I., Bergman, B., Ayoub, J., Richardson, G., Dunlop, D., Arcenas, A., Vescio, R., Viallet, J., Treat, J.: Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J. Clin. Oncol. 18, 1351–1359 (2000)
26. Peters, L.J., O’Sullivan, B., Giralt, J., Fitzgerald, T.J., Trotti, A., Bernier, J., Bourhis, J., Yuen, K., Fisher, R., Rischin D.: Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: Results from TROG 02.02. J. Clin. Oncol. 28, 2996–3001 (2010)
27. Pries, A.R., Cornelissen, A.J., Sloot, A.A., Hinkeldey, M., Dreher, M.R., Hoepfner, M., Dewhirst, M.W., Secomb, T.W.: Structural adaptation and heterogeneity of normal and tumor microvascular networks. PLoS Comput. Biol. 5, e1000394 (2009)
28. Pries, A.R., Hopfner, M., le Noble, F., Dewhirst, M.W., Secomb, T.W.: The shunt problem: control of functional shunting in normal and tumour vasculature. Nat. Rev. Cancer 10, 587–593 (2010)
29. Pruijn, F.B., Patel, K., Hay, M.P., Wilson, W.R., Hicks, K.O.: Prediction of tumour tissue diffusion coefficients of hypoxia-activated prodrugs from physicochemical parameters. Aust. J. Chem. 61, 687–693 (2008)
30. Rischin, D., Fisher, R., Peters, L., Corry, J., Hicks, R.: Hypoxia in head and neck cancer: Studies with hypoxic positron emission tomography and hypoxic cytotoxins. Int. J. Radiat. Oncol. Biol. Phys.69 (Suppl 2), S61-S63 (2007)
31. Rischin, D., Peters, L.J., O’Sullivan, B., Giralt, J., Fisher, R., Yuen, K., Trotti, A., Bernier, J., Bourhis, J., Ringash, J., Henke, M., Kenny, L.: Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): A phase III trial of the Trans-Tasman Radiation Oncology Group. J. Clin. Oncol. 28, 2989–2995 (2010)
32. Secomb, T.W., Dewhirst, M.W., Pries, A.R.: Structural adaptation of normal and tumour vascular networks. Basic Clin. Pharmacol. Toxicol. 110, 63–69 (2012)
33. Secomb, T.W., Hsu, R., Braun, R.D., Ross, J.R., Gross, J.F., Dewhirst, M.W.: Theoretical simulation of oxygen transport to tumors by three-dimensional networks of microvessels. Adv. Exp. Med. Biol. 454, 629–634 (1998)
34. Secomb, T.W., Hsu, R., Park, E.Y., Dewhirst, M.W.: Green’s function methods for analysis of oxygen delivery to tissue by microvascular networks. Ann. Biomed. Eng. 32, 1519–1529 (2004)
35. Shinde, S.S., Hay, M.P., Patterson, A.V., Denny, W.A., Anderson, R.F.: Spin trapping of radicals other than the *OH radical upon reduction of the anticancer agent tirapazamine by cytochrome P450 reductase. J. Am. Chem. Soc. 131, 14220–14221 (2009)
36. Vaupel, P., Hockel, M., Mayer, A.: Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal 9, 1221–1235 (2007)
37. Vaupel P., Mayer, A.: Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 26, 225–239 (2007)
38. Walton, M.I., Workman, P.: Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice. J. Pharmacol. Exp. Ther. 265, 938–947 (1993)
39. Wilson, D.F., Evans, S.M., Jenkins, W.T., Vinogradov, S.A., Ong, E., Dewhirst, M.W.: Oxygen distributions within R3230Ac tumors growing in dorsal flap window chambers in rats. Adv. Exp. Med. Biol. 454, 603–609 (1998)
40. Wilson, W.R., Hay, M.P.: Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 11, 393–410 (2011)
41. Wouters, B.G., Brown, J.M.: Cells at intermediate oxygen levels can be more important than the “hypoxic fraction” in determining tumor response to fractionated radiotherapy. Radiat. Res. 147, 541–550 (1997)
42. Zeman, E.M., Brown, J.M., Lemmon, M.J., Hirst, V.K., Lee, W.W.: SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys. 12, 1239–1242 (1986)